Aldeyra Therapeutics, Inc.(ALDX)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.0M in revenue and is scored on the micro-cap board instead.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
ALDX Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for Aldeyra Therapeutics, Inc. (ALDX), a Healthcare sector company. ALDX is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.0m in revenue and is scored on the micro-cap board instead. Top institutional holders of ALDX by reported 13-F value include Knoll Capital Management, AQR CAPITAL MANAGEMENT, KINGDON CAPITAL MANAGEMENT, L.L.C., based on the most recent SEC filings. ALDX trades on the Nasdaq exchange and files with the SEC under CIK 1341235. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ALDX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Aldeyra Therapeutics, Inc. directly from SEC EDGAR.
Net Income
Q2 2026
$-5.5M
ROIC
Q2 2026
-61.8%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProNet Income
+39.4% YoYOperating Income
+41.3% YoYEPS (Diluted)
+40.4% YoYTotal Assets
-31.1% YoYTotal Debt
+99.3% YoYOp. Cash Flow
+22.8% YoYFree Cash Flow
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Net Income | $-33.8M +39.4% | $-55.9M -48.8% | $-37.5M +39.5% | $-62.0M -7.4% | $-57.8M -53.8% | $-37.6M |
| Operating Income | $-35.3M +41.3% | $-60.1M -40.5% | $-42.8M +31.7% | $-62.7M -11.5% | $-56.2M -54.4% | $-36.4M |
| EPS (Diluted) | $-0.56 +40.4% | $-0.94 -46.9% | $-0.64 +39.6% | $-1.06 +0.9% | $-1.07 | — |
| Total Assets | $72.1M -31.1% | $104.6M -29.5% | $148.3M -18.2% | $181.3M -22.2% | $233.1M +179.7% | $83.4M |
| Total Debt | $30.5M +99.3% | $15.3M -49.6% | $30.4M +76.5% | $17.2M +7.5% | $16.0M +0.0% | $16.0M |
| Operating Cash Flow | $-33.3M +22.8% | $-43.2M -42.5% | $-30.3M +46.5% | $-56.6M -33.1% | $-42.6M -13.5% | $-37.5M |
| Free Cash Flow | — | — | $-30.3M +46.5% | $-56.7M -33.1% | $-42.6M | — |
Get alerted when ALDX's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Aldeyra Therapeutics, Inc. including:
Top Institutional Holders of ALDX
Knoll Capital Management, LLC
$11.7M5,475,516 shAQR CAPITAL MANAGEMENT LLC
$8.0M3,751,558 shKINGDON CAPITAL MANAGEMENT, L.L.C.
$5.6M2,652,315 shVANGUARD CAPITAL MANAGEMENT LLC
$5.0M2,361,796 shD. E. Shaw & Co., Inc.
$4.1M1,940,338 shMARSHALL WACE, LLP
$3.2M1,506,974 sh683 Capital Management, LLC
$3.1M1,450,000 shJANE STREET GROUP, LLC
$2.9M1,375,115 shBlackRock, Inc.
$2.7M1,257,243 shQube Research & Technologies Ltd
$2.4M1,128,803 sh
| Fund | Value | Shares |
|---|---|---|
| Knoll Capital Management, LLC | $11.7M | 5,475,516 |
| AQR CAPITAL MANAGEMENT LLC | $8.0M | 3,751,558 |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | $5.6M | 2,652,315 |
| VANGUARD CAPITAL MANAGEMENT LLC | $5.0M | 2,361,796 |
| D. E. Shaw & Co., Inc. | $4.1M | 1,940,338 |
| MARSHALL WACE, LLP | $3.2M | 1,506,974 |
| 683 Capital Management, LLC | $3.1M | 1,450,000 |
| JANE STREET GROUP, LLC | $2.9M | 1,375,115 |
| BlackRock, Inc. | $2.7M | 1,257,243 |
| Qube Research & Technologies Ltd | $2.4M | 1,128,803 |
More Healthcare Companies
View all Healthcare →Put ALDX on your watchlist
Track score changes the day Aldeyra Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is ALDX a good stock to buy?
13F Pro's AI-powered analysis of Aldeyra Therapeutics, Inc. (ALDX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ALDX are available on the ALDX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. ALDX is classified as a small company.
Which hedge funds own ALDX?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ALDX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Aldeyra Therapeutics, Inc.'s investment landscape.